Cyclosporine arteriolopathy: Effects of drug withdrawal

被引:33
作者
Franceschini, N
Alpers, CE
Bennett, WM
Andoh, TF
机构
[1] Oregon Hlth & Sci Univ, Div Nephrol Hypertens & Clin Pharmacol, Portland, OR 97201 USA
[2] Univ Washington, Dept Pathol, Seattle, WA 98195 USA
关键词
cyclosporine; chronic nephrotoxicity; arteriolopathy; arteriolohyalinosis;
D O I
10.1053/ajkd.1998.v32.pm9708608
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Renal arteriolopathy in chronic cyclosporine-induced nephrotoxicity is characterized by an eosinophilic granular transformation of vascular smooth muscle cells of afferent glomerular arterioles that is thought to eventually progress to necrosis of individual muscle cells and hyalinization of the vessel wall. Although the lesion is highly specific for cyclosporine-induced injury in humans, it has been difficult to reproduce in normotensive animals. To study the natural history of the cyclosporine arteriolopathy, we conducted sequential studies in salt-depleted Sprague-Dawley rats using cyclosporin A (15 mg/kg subcutaneously) treatment for 35 days, 49 days, 35 days plus 14 or 56 days of drug washout, or placebo (olive oil). Cyclosporin A produced a progressive decrease in renal function that significantly improved after discontinuation of the drug. The arteriolopathy, scored semiquantitatively, was present by day 35 and did not improve with cyclosporine withdrawal within 2 weeks but did dramatically regress after 56 days. However, tubulointerstitial changes did not regress with drug discontinuation and were present despite improvement in renal function. We conclude that cyclosporine induced arteriolopathy may be reversible and associated with improving renal function. Thus, the morphological evidence of arteriolopathy is dissociable from the progressive tubulointerstitial scarring. (C) 1998 by the National Kidney Foundation, Inc.
引用
收藏
页码:247 / 253
页数:7
相关论文
共 26 条
  • [1] ANTONOVYCH TT, 1988, TRANSPL P, V20, P951
  • [2] BENNETT WM, 1994, MINER ELECTROL METAB, V20, P214
  • [3] PREVENTION OF EXPERIMENTAL CYCLOSPORINE-INDUCED INTERSTITIAL FIBROSIS BY LOSARTAN AND ENALAPRIL
    BURDMANN, EA
    ANDOH, TF
    NAST, CC
    EVAN, A
    CONNORS, BA
    COFFMAN, TM
    LINDSLEY, J
    BENNETT, WM
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 1995, 269 (04) : F491 - F499
  • [4] REVERSIBLE CYCLOSPORINE ARTERIOLOPATHY
    COLLINS, BS
    DAVIS, CL
    MARSH, CL
    MCVICAR, JP
    PERKINS, JD
    ALPERS, CE
    [J]. TRANSPLANTATION, 1992, 54 (04) : 732 - 734
  • [5] ELZINGA LW, 1993, J AM SOC NEPHROL, V4, P214
  • [6] RISK-FACTORS FOR CYCLOSPORINE-INDUCED NEPHROPATHY IN PATIENTS WITH AUTOIMMUNE-DISEASES
    FEUTREN, G
    MIHATSCH, MJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (25) : 1654 - 1660
  • [7] ENDOTHELIN RECEPTOR ANTAGONISM IS PROTECTIVE IN INVIVO ACUTE CYCLOSPORINE TOXICITY
    FOGO, A
    HELLINGS, SE
    INAGAMI, T
    KON, V
    [J]. KIDNEY INTERNATIONAL, 1992, 42 (03) : 770 - 774
  • [8] HUNLEY TE, 1995, J AM SOC NEPHROL, V5, P1718
  • [9] MASON J, 1991, KIDNEY INT, V39, pS28
  • [10] MIHATSCH MJ, 1988, TRANSPLANT P, V20, P759